Selecta Biosciences to Present at the Raymond James 2020 Human Healthcare Innovation Conference
June 15, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
June 11, 2020 17:15 ET
|
Selecta Biosciences, Inc.
- Strategic licensing agreement for SEL-212, a unique phase 3-ready therapy powered by Selecta’s breakthrough immune tolerance platform, ImmTOR™, with the potential to fulfil a significant unmet need...
Selecta Biosciences to Present at the Jefferies Virtual Healthcare Conference
May 26, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Reports First Quarter 2020 Financial Results
May 07, 2020 07:30 ET
|
Selecta Biosciences, Inc.
- Topline data announcement from the ongoing head-to-head COMPARE trial of SEL-212 remains on schedule for Q3 2020 - - Phase 3 clinical program of SEL-212 to commence in 2H 2020 - - Ongoing COVID-19...
Selecta Biosciences to Present at the Bank of America Merrill Lynch 2020 Health Care Conference
May 05, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Recent Operational Highlights
April 30, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Appoints Dr. Goran Ando to its Board of Directors
April 28, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference
April 07, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial Results
March 12, 2020 08:00 ET
|
Selecta Biosciences, Inc.
- Topline results from head-to-head COMPARE trial of SEL-212 in chronic refractory gout expected in Q3 2020 - - Received guidance from the FDA on SEL-212 Phase 3 clinical trial design; study to...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
March 05, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...